Anthony @ Equity Investigations, Dear Anthony, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony,

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony@Pacific who wrote ()	4/14/2000 4:28:00 AM
From: scott_jiminez	Read Replies (2) of 122087

I come to this thread following a site search for Ariad Pharmaceuticals, one of those companies cited in the Wired article as an Anthony rapid-fire 25% short gain. Anthony's assessment of the company was 'pure diarrhea'. I was a shareholder of Ariad at that time in January. I reduced my position by ~90% in March because the stock had become far to large a fraction of my portfolio. And that is my point. Anthony went in to Ariad at $9, out at $7 in January - for a quick profit. Completely legit and I suppose a good heads up. However, it is certainly of questionable conduct, if not downright deceptive to NOT reveal what happened with the stock subsequent to those 2 days in January. The retelling of Ariad's performance was far from complete. Within one month of Anthony's trade, the stock had gone up 600% to peak at $48 at the beginning of March. It has since come back down to $11....in sync with the rest of the biotech sector. In addition... Anthony's assessment that Ariad's receiving 2 new patents should be the catalyst for shorting the stock was so incredibly ignorant (in fact, there were countless intelligent reasons for potentially shorting ARIA) of the role of patents in establishing the legitimacy of biotechnology companies so as to completely undermine the Ariad story line in the Wired article. The Ariad patent announcements were NOT expected. And the reaction to the patent news was not the immediate 25% drop within 24 hours but the 600% rise during the following 40 days. Ariad has come back down with entire sector - and you could have thrown a dart at ANY biotech company at the beginning of March and made a fortune shorting it. That's not skill nor insight. That's a child's common sense. In a similar vein, I can view the world through rose-colored glasses like Anthony does: I can tell the Wired reporter how I made a quick 25% by spotting Ariad's diarrhea....simply 'forgetting' to mention that if I had held the stock LONG from that point for 4 weeks I would have made 600%. In fact, an investor who bought Ariad at $7 in January and sold tomorrow, after this HUGE correction in the biotechs, would STILL come out ahead of Anthony's trade in Ariad. Thus it appears in the case of Ariad, and I strongly suspect for many of the other stocks Anthony claims insight, that the bonafide source of diarrhea is from a very deep internal well within the 'master' himself, immersing his eyes and brain in a very rich, and pungent, brown hue.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next